Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C | P18825 | 1/20 | 0.57 |
| ▸ | FNTA | P49354 | 4/20 | 0.47 |
| ▸ | FNTB | P49356 | 4/20 | 0.47 |
| ▸ | PGGT1B | P53609 | 4/20 | 0.47 |
| ▸ | TACR1 | P25103 | 1/20 | 0.45 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.45 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.43 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6165356 | 0.90 | ADRA2C (0.58) | ADRA2CFNTAFNTBPGGT1BTACR1 | |
| SCHEMBL6162276 | 0.87 | TACR1 (0.47) | FNTAFNTBPGGT1BTACR1MAOB | |
| SCHEMBL6163151 | 0.86 | ADRA2C (0.47) | ADRA2CFNTAFNTBPGGT1BTACR1 | |
| SCHEMBL6166155 | 0.75 | ADRA2C (0.68) | ADRA2CGABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL28725605 | 0.75 | ADRA2C (0.68) | ADRA2CHCAR2GABRG2GABRB3GABRA5 | |
| SCHEMBL6167622 | 0.75 | ADRA2C (0.77) | ADRA2CHCAR2GABRG2GABRB3GABRA5 | |
| SCHEMBL10980808 | 0.75 | ADRA2C (0.68) | ADRA2CHCAR2GABRG2GABRB3GABRA5 | |
| SCHEMBL6165241 | 0.75 | ADRA2C (0.68) | ADRA2CHCAR2GABRG2GABRB3GABRA5 | |
| Water SCHEMBL9538330 | 0.74 | TACR1 (0.62) | TACR1 | |
| SCHEMBL7062567 | 0.74 | MAOB (0.69) | MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1254136-A4 | FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF | LG CHEM INVESTMENT LTD (KR) | 2005-06-01 | — | — | EP | disclosed |
| US-20030065176-A1 | Factor xa inhibitors with aryl-amidines and derivatives, and prodrugs thereof | LG CHEM INVESTMENT LTD. (KR) | 2003-04-03 | — | — | US | disclosed |
| EP-1254136-A1 | FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF | LG Chem Investment, Ltd. (KR) | 2002-11-06 | — | — | EP | disclosed |
| WO-2001055146-A1 | FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF | LG CHEM INVESTMENT LTD. (KR) | 2001-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065176-A1 | Factor xa inhibitors with aryl-amidines and derivatives, and prodrugs thereof | F2, F12, TFPI | ADRA2C 1810/4885FNTA 654/4885FNTB 1197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.